During the MCI stage, clinicians may be able to detect very early features of AD that are distinct from other causes of memory loss or other forms of cognitive impairment.2,3
These features can be detected using validated tools such as Mini-Cog, General Practitioner Assessment of Cognition (GPCOG), Memory Impairment Screen (MIS), and Montreal Cognitive Assessment (MoCA).3,4
In one study of patients with amyloid beta–positive (Aβ+) MCI, the median time to progression was estimated to be 2 years:
PET imaging and CSF tests can determine whether amyloid beta (Aβ) and/or tau pathology is present in the brain. These biomarkers are currently considered valid proxies for neuropathologic changes of AD and are included in the ATN classification system. Recent recommendations by the International Working Group (IWG) require both clinical and biological diagnosis of AD. Although Aβ and tau biomarkers are not sufficient to predict progression or identify a stage of AD on their own, they are necessary to make an AD diagnosis.
ATN=amyloid beta, tau, neurodegeneration.
Early and accurate diagnosis of Alzheimer's disease is important for patient care. Identifying biomarkers may serve as the mechanism to improve early and accurate diagnosis.11,12